Get the Stockscreener App
91.01
0.14%
-0.13
Ani Pharmaceuticals Inc stock is traded at $91.01, with a volume of 432.20K.
It is down -0.14% in the last 24 hours and up +37.19% over the past month.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
See More
Previous Close:
$91.14
Open:
$91.56
24h Volume:
432.20K
Relative Volume:
1.03
Market Cap:
$1.97B
Revenue:
$486.82M
Net Income/Loss:
$18.78M
P/E Ratio:
110.99
EPS:
0.82
Net Cash Flow:
$100.45M
1W Performance:
+4.05%
1M Performance:
+37.19%
6M Performance:
+57.08%
1Y Performance:
+50.38%
1-Day Range:
$90.77
$92.53
1-Week Range:
$87.31
$92.53
52-Week Range:
$52.50
$92.53
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Name
Ani Pharmaceuticals Inc
Sector
Phone
(218) 634-3500
Address
210 MAIN STREET WEST, BAUDETTE, MN
Compare ANIP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
91.01 | 1.95B | 486.82M | 18.78M | 100.45M | 0.82 |
|
ZTS
Zoetis Inc
|
156.62 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.52 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.46 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
312.23 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Initiated | H.C. Wainwright | Buy |
| Mar-14-25 | Initiated | Jefferies | Buy |
| Mar-12-25 | Initiated | JP Morgan | Overweight |
| Dec-11-24 | Initiated | Leerink Partners | Outperform |
| Oct-11-24 | Initiated | Piper Sandler | Overweight |
| Mar-15-24 | Initiated | CapitalOne | Overweight |
| Aug-22-23 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Sep-07-22 | Initiated | H.C. Wainwright | Buy |
| Nov-02-21 | Initiated | Truist | Buy |
| May-07-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| May-10-19 | Downgrade | Raymond James | Strong Buy → Outperform |
| Oct-16-17 | Reiterated | Canaccord Genuity | Buy |
| Jul-31-17 | Initiated | Canaccord Genuity | Buy |
| Feb-22-17 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-23-16 | Initiated | Raymond James | Strong Buy |
| May-24-16 | Downgrade | Standpoint Research | Buy → Hold |
| Nov-13-15 | Initiated | Standpoint Research | Buy |
| Sep-28-15 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-05-15 | Reiterated | Oppenheimer | Outperform |
| Aug-04-15 | Reiterated | ROTH Capital | Neutral |
| Jul-31-15 | Reiterated | Oppenheimer | Outperform |
| Jul-15-15 | Reiterated | ROTH Capital | Neutral |
| Jun-23-15 | Reiterated | Oppenheimer | Outperform |
| May-18-15 | Reiterated | ROTH Capital | Neutral |
| May-06-15 | Reiterated | Oppenheimer | Outperform |
| Apr-10-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-26-15 | Reiterated | ROTH Capital | Buy |
| Feb-18-15 | Reiterated | Oppenheimer | Outperform |
View All
Ani Pharmaceuticals Inc Stock (ANIP) Latest News
MACD Signals Flash Warning for ANI Pharmaceuticals Inc. StockMarket Performance Recap & Fast Entry High Yield Tips - newsyoung.net
Ani Pharmaceuticals stock hits 52-week high at 90.43 USD By Investing.com - Investing.com Nigeria
Ani Pharmaceuticals Executives Sell Shares Amid Market Volatility - AInvest
ANI Pharmaceuticals' Insider Sales: Strategic Liquidity or a Warning Signal for Shareholders? - AInvest
Insider Selling at ANI Pharmaceuticals: A Cautionary Signal Amidst Strong Earnings and Analyst Optimism? - AInvest
Shanmugam Muthusamy of Ani Pharmaceuticals sells $8.8m in stock - Investing.com
Ani Pharmaceuticals Insider Sold Shares Worth $801,450, According to a Recent SEC Filing - MarketScreener
Shanmugam Muthusamy of Ani Pharmaceuticals sells $8.8m in stock By Investing.com - Investing.com UK
Ani Pharmaceuticals stock hits 52-week high at 90.43 USD - Investing.com India
Momentum Screeners Rank ANI Pharmaceuticals Inc. in Top 5 Today2025 Institutional Moves & Real-Time Volume Analysis Alerts - classian.co.kr
Will ANI Pharmaceuticals Inc. Hold Gains Into CloseMarket Weekly Review & Consistent Income Trade Ideas - newsimpact.co.kr
ANI gets FDA approval for generic Motegrity - MSN
ANI Pharmaceuticals, Berkshire Hathaway, Chevron - TradingView
Using R and stats models for ANI Pharmaceuticals Inc. forecastingStop Loss & Weekly Top Gainers Trade List - Newser
Advanced analytics toolkit walkthrough for ANI Pharmaceuticals Inc.Market Performance Recap & Real-Time Sentiment Analysis - Newser
ANI Pharmaceuticals Inc. stock daily chart insights2025 Support & Resistance & Risk Managed Investment Strategies - Newser
Published on: 2025-08-17 01:40:35 - Newser
ANI Pharmaceuticals Inc. stock outlook for YEAR2025 Major Catalysts & AI Powered Buy/Sell Recommendations - Newser
Trend analysis for ANI Pharmaceuticals Inc. this weekWeekly Trade Analysis & Fast Moving Stock Trade Plans - Newser
This Insider Has Just Sold Shares In ANI Pharmaceuticals - simplywall.st
ANI Pharmaceuticals Inc.’s Price Action Aligns with Quant SignalsConsistent High Return Strategy - beatles.ru
Technical signs of recovery in ANI Pharmaceuticals Inc.July 2025 Short Interest & Breakout Confirmation Trade Signals - Newser
ANI Pharmaceuticals (NASDAQ:ANIP) Stock Rating Upgraded by Wall Street Zen - Defense World
Assessing Insider Selling at ANI Pharmaceuticals: Confidence or Concern? - AInvest
Chart based exit strategy for ANI Pharmaceuticals Inc.July 2025 PostEarnings & AI Based Buy/Sell Signal Reports - Newser
Nikhil Lalwani Sells 56,960 Shares of ANI Pharmaceuticals Inc, Insider Now Owns 411,219 Shares - AInvest
Leerink Partners Maintains Buy Rating on ANI Pharmaceuticals with $100 Price Target - AInvest
ANI Pharmaceuticals Inc. recovery potential after sell offJuly 2025 Setups & Entry and Exit Point Strategies - Newser
ANI Pharmaceuticals' Insider Sale: A Strategic Warning or a Misread Opportunity? - AInvest
The 5 Most Interesting Analyst Questions From ANI Pharmaceuticals’s Q2 Earnings Call - Yahoo Finance
Can ANI Pharmaceuticals Inc. Overcome Bearish SentimentBear Alert & Smart Allocation Stock Reports - sundaytimes.kr
Nikhil Lalwani, president of ANI Pharmaceuticals, sells $4.89m in stock - Investing.com Nigeria
Ani Pharmaceuticals SVP, Gutwerg, sells $508,190 in stock By Investing.com - Investing.com Nigeria
Ani Pharmaceuticals SVP, Gutwerg, sells $508,190 in stock - Investing.com
ANI Pharmaceuticals director Haughey sells $1.66 million in stock - Investing.com
Ani Pharmaceuticals SVP Carey sells $4.3m in shares By Investing.com - Investing.com Australia
Ani Pharmaceuticals’ Cook sells $35k in stock - Investing.com
Ani Pharmaceuticals SVP Carey sells $4.3m in shares - Investing.com India
Rowland, SVP at Ani Pharmaceuticals, sells $426k in stock - Investing.com India
ANI Pharmaceuticals director Haughey sells $1.66 million in stock By Investing.com - Investing.com Canada
Rowland, SVP at Ani Pharmaceuticals, sells $426k in stock By Investing.com - Investing.com Australia
ANI Pharmaceuticals' Insider Sales: Liquidity or Lack of Confidence? - AInvest
Insider Selling at ANI Pharmaceuticals: Liquidity Moves or Lack of Confidence? - AInvest
Council approves plans for pharmaceutical manufacturing facility - veronapress.com
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q2 2025 Earnings Call Transcript - MSN
Azenta, LifeStance Health Group, BioMarin Pharmaceutical, AMN Healthcare Services, and ANI Pharmaceuticals Stocks Trade Up, What You Need To Know - Yahoo Finance
Azenta, LifeStance Health Group, BioMarin Pharmaceutical, AMN Healthcare Services, and ANI Pharmaceuticals Stocks Trade Up, What You Need To Know | FinancialContent - FinancialContent
ANI Pharmaceuticals (NASDAQ:ANIP) Stock Price Expected to Rise, Truist Financial Analyst Says - Defense World
ANI Pharmaceuticals Inc. Surpasses Analyst Target Price of $83.12 - AInvest
Ani Pharmaceuticals Inc Stock (ANIP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ani Pharmaceuticals Inc Stock (ANIP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Leonard Matthew J | Director |
Aug 18 '25 |
Sale |
88.17 |
6,937 |
611,635 |
9,392 |
| Walsh Patrick D | Director |
Aug 15 '25 |
Sale |
89.05 |
9,000 |
801,450 |
70,048 |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS |
Aug 15 '25 |
Sale |
87.15 |
52,990 |
4,618,078 |
531,920 |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS |
Aug 14 '25 |
Sale |
89.48 |
47,010 |
4,206,455 |
584,910 |
| Gassert Chad | SVP - CORP. DEV. & STRATEGY |
Aug 15 '25 |
Sale |
86.97 |
20,000 |
1,739,400 |
173,226 |
2.37%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):